A sensitive and accurate liquid chromatography–tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine
Authors:
- Hao JiangHJHao Jiang
- Jianing ZengJZJianing Zeng
- Hamza KandoussiHKHamza Kandoussi
- Yifei LiuYLYifei Liu
- Xiaodong WangXWXiaodong Wang
- Marc BifanoMBMarc Bifano
- Laura CojocaruLCLaura Cojocaru
- John RyanJRJohn Ryan
- Mark E. ArnoldMAMark E. Arnold
- 6 July 2012
- journal article
- research article
- Published by Elsevier in Journal of Chromatography A
- Vol. 1245, 117-121
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Development and validation of a sensitive LC/MS/MS method for the simultaneous determination of naloxone and its metabolites in mouse plasmaJournal of Chromatography B, 2011
- The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still PendingGastroenterology, 2011
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature, 2010
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002